GIS:FRA
Gilead Sciences, Inc
155,24 €
arrow_upward
+0,01%(+0,020) 1 p
17. nov, 15:58:19 GMT +1 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse GIS põhistatistika genereerimine…
Ava
151,84 €
Kõrge
155,24 €
Madal
151,84 €
Turu kapit.
210,60 mld
Keskm. maht
224,00
Maht
643,00
52 näd kõrgeim
157,14 €
52 näd madalaim
100,42 €
Töötajate arv
17 tuh
Ava
151,84 €
Kõrge
155,24 €
Madal
151,84 €
Turu kapit.
210,60 mld
Keskm. maht
224,00
Maht
643,00
52 näd kõrgeim
157,14 €
52 näd madalaim
100,42 €
Töötajate arv
17 tuh
Uudised
Veebiallikatest ja uudistepartneritelt
Investing.com Canada
·
48 minuti eest
Gilead at Jefferies Global Healthcare Conference: growth broadens By Investing.com
Pharmaceutical Executive
·
48 minuti eest
Gilead Signs Royalty-Free Licensing Deals to Broaden Access to Obeldesivir
Yahoo Finance
·
55 minuti eest
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
Yahoo Finance
·
2 tunni eest
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
Profiil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Teave üksuse Gilead Sciences, Inc kohta
TegevjuhtDaniel O'Day
Töötajad17 tuh
Asutatud22. juuni 1987
PeakontoridFoster City, California, Ameerika Ühendriigid
SektorHealth Care
Valdkond-
Veebisaitgilead.com